ArriVent BioPharma, Inc. Common Stock

AVBP · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$80,488-$69,333-$36,906-$51,606
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$3,208$895$424$0
Change in WC$7,068$12,596-$7,149-$3,941
Other Non-Cash$0$0$0$42,960
Operating Cash Flow-$70,212-$55,842-$43,631-$12,587
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$194,164-$25,000$0$0
Inv. Sales/Matur.$1,699$25,000$0$0
Other Inv. Act.$0$0$0-$40,000
Investing Cash Flow-$192,465$0$0-$40,000
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$185,950$0$2$89,867
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$631$42,859$169,721$0
Financing Cash Flow$186,581$42,859$169,723$89,867
Forex Effect$0$0$0$0
Net Chg. in Cash-$76,096-$12,983$126,092$37,280
Supplemental Information
Beg. Cash$150,389$163,372$37,280$0
End Cash$74,293$150,389$163,372$37,280
Free Cash Flow-$70,212-$55,842-$43,631-$12,587